NCT03253536Recruiting
Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 18 Aug 2017 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Prospective single arm, single center observational study to evaluate Quality of Life (Qol) after stereotactic body radiotherapy for patients with hepatocellular cancer. Patients will receive work-up, treatment and follow-up exclusively as routinely done except additional quality of life measurements. Qol will be measured by standardized and validated EORTC questionaires at different time points during routine follow-up.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 14 Aug 2017
- Start date
- 10 Jul 2017
- Primary completion date
- 10 Jul 2022
- Lead sponsor
- Ludwig-Maximilians - University of Munich
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT03253536
What you commit to
- Study type: Observational
- Planned participants: 100
- From 10 Jul 2017 to the primary completion date, 10 Jul 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- prior HCC specific systemic therapy
- concurrent oncological systemic treatment
Age
- age \< 18 years
Other
- distant metastases
- inadequate ability tobe compliant with the protocol or to complete standardizes questionaires
- inability to receive contrast-enhanced planning CT
- missing ability to give informed consent
- legal custody
Who the study is looking for
- histologically or radiologically proven hepatocellular carcinoma
- 1-3 lesions suitable for stereotactic radiation therapy
- indication for SBRT according to multidisciplinary board evaluation
- age \>= 18 years
- written informed consent for study participation
- mental and verbal ability to complete standardized questionaires according to assessment by investigator (physician)
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Radiation Oncology, University Hospital, LMU Munich Coordinator of this site? Confirm its status | Munich | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.